Enlivex Therapeutics Ltd.
ENLV | NASDAQ
$1.29
-$0.10 (-7.19%)
At close: Nov 5, 2026, 3:59 PM ET
$1.35
+$0.06 (+4.65%)
After-hours:
Nov 5, 2026, 5:16 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | 2.28M |
Cost of Revenue | 332K | 545K | 835K | 777K | 546K | 286K |
Gross Profit | -332K | -545K | -835K | -777K | -546K | -286K |
Operating Income | -15M | -15.54M | -29.4M | -25.8M | -19.29M | -9.79M |
Interest Income | 792K | 1.07M | 1.57M | 835K | 120K | 225K |
Pretax Income | 1.62B | -15.01M | -29.07M | -31.06M | -14.47M | -11.82M |
Net Income | 1.24B | -15.01M | -29.07M | -31.06M | -14.47M | -11.82M |
Selling & General & Admin | 5.69M | 4.91M | 6.14M | 6.7M | 6.24M | 3.6M |
Research & Development | 8.92M | 10.13M | 19.24M | 18.69M | 12.88M | 6.09M |
Other Expenses | 61K | -48K | 4.02M | 402K | 167K | 97K |
Operating Expenses | 14.67M | 14.99M | 29.4M | 25.8M | 19.29M | 9.79M |
Interest Expense | 13K | 13K | 14K | 5.26M | 328K | 6K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 15M | 15.54M | 29.4M | 25.8M | 19.29M | 8.57M |
Income Tax Expense | 382.65M | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 190.4K | 85.48K | 77.39K | 76.65K | 74.42K | 54.87K |
Shares Outstanding (Diluted) | 202.08K | 85.48K | 77.39K | 76.65K | 74.42K | 54.87K |
EPS (Basic) | 6.49K | -175.20 | -374.40 | -554.40 | -129.60 | -252 |
EPS (Diluted) | 6.12K | -175.20 | -374.40 | -554.40 | -129.60 | -252 |
EBITDA | -14.67M | -14.47M | -28.22M | -25.02M | -18.74M | -9.5M |
EBIT | -15M | -15.01M | -29.05M | -25.8M | -19.29M | -9.79M |
Depreciation & Amortization | 332K | 545K | 835K | 777K | 546K | 286K |
Add to Watchlist
Select watchlists to add or remove ENLV